ABSTRACT PURPOSE: To investigate the possible protective effect of thymoquinone (TQ) in cisplatin (CP) induced myocardial injury.
Introduction
Cisplatin is an effective chemotherapeutic drug that belonging to platinum relating agents used in oncological applications. CP-based treatment is very effective in different cancer types involving pulmonary, ovarian, cranial, cervical and gastric tissues cancers 1, 2 . However, the optimal efficacy of CP use is generally restricted by toxic effects such as nephrotoxicity, ototoxicity and cardiovascular complications 3, 4 . CP-induced cardiotoxicity which is characterized by various findings including electrocardiographic changes, arrhythmia, cardiomyopathy and congestive heart failure has been reported in numerous studies.
Although huge efforts were made over many years to find out more powerful but less toxic agents, CP is still widely prescribed 5 .
Mechanisms underlying anti-tumoral activity of CP is wellknown, however cellular and molecular factors which cause CP-induced cardiotoxicity are still unclear. On the other hand, several experimental and clinical studies support the idea that the enhancement of oxidative stress may involve in this insult 6 .
Thymoquinone is a bioactive compound mainly established from the Nigella sativa plant. TQ is known to have potent antioxidant and anti-inflammatory features, but it is also used in widely range of other fields such as cancer treatment 7 .
In some previous studies, it has been reported that TQ treatment protected organs against oxidative damage induced by different free radical producing agents like carbon tetrachloride, cisplatin and doxorubicin 8, 9 . Different agents with antioxidant, modulators of nitric oxide, diuretic, cytoprotective and antiapoptotic properties have been used to avoid CP nephrotoxicity [10] [11] [12] . However, there are few studies focused on reducing the cardiotoxicity of CP in the literature.
In the current study, we aimed to investigate the protective and antiapoptotic effects of TQ on CP-induced cardiotoxicity by evaluating immunohistochemical and histopathological results.
To best of our knowledge, this is the first study to evaluate the antiapoptotic and protective effects of TQ against myocardial damage induced by CP in rats.
Methods
This study was approved by the Ethical Committee on 
Termination of the experiment
At the end of the study, rats were anesthetized with 50 mg/kg of ketamine hydrochloride (Ketalar; Eczacibasi Ilac Sanayi ve Ticaret A.S., Luleburgaz, Turkey) and 10 mg/kg of xylazine (Alfazyne; Alfasan International B.V., Woerden, the Netherlands) and immediately sacrificed by exsanguination. Hearts were removed, cleaned and washed in ice-cold phosphate buffered saline (pH 7.4). One piece of each heart tissue was taken from left ventricule and this sample was fixed in 10% formalin solution for histopathological analysis.
Histopathological examination
Heart samples were fixed with 10% neutral formalin, have undergone routine tissue processing steps and embedded in paraffin. Sections at five micrometers thickness were cut from paraffin blocks and stained with hematoxylin-eosin (H&E) dye.
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Image analysis
Sections were evaluated under light microscope (Eclipse E-600 Nikon, Japan) by using an image analysis software (NIS Elements, Nikon, Tokyo, Japan). Slides stained with hematoxylineeosin were evaluated in terms of congestion, edema and pycnotic nuclei parameters in randomly chosen six different areas in each slide under x40 objective magnification. The slides were scored according to the method described by Demir et al. 14 were considered as statistically significant.
Results

The effects of thymoquinone on myocardial damage
Routinely stained heart sections were given in Figure   1 . In histopathological examination, myocardial fibers were observed normal morphology in control group ( Figure 1A ). There was an increase in congestion, edema, eosinophilic cytoplasm and pycnotic nuclei parameters in CP group than the controls (p=0.002, p=0.001, p=0.026 and p=0.001, respectively) ( Figure   1B ). There was a statistically significant difference between the CP and CP plus TQ groups with in these parameters except for eosinophilic cytoplasm (p=0.004, p=0.004, p=0.017 and p=0.001, respectively) and it was observed that additional TQ treatment led to an improvement in histopathological scores ( Figure 1C ). Only TQ given group exhibited less increment in mentioned parameters than the CP group (p=0.004, p=0.001, p=0.038 and p=0.001, respectively) ( Figure 1D ). There was no difference between the control and TQ groups here was no difference between the control and TQ groups here was no difference between the control and TQ groups. The related results were given in Table 1 . 
The effects of thymoquinone on expression of antiapoptotic protein Bcl-2
Sections stained with Bcl-2 primary antibody were represented in Figure 2 . Diffuse and cytoplasmic stainings were assessed in myocardial tissue slides. In control group, some of the myocardial fibers have demonstrated moderate expressions of Bcl-2 ( Figure 2A ). In only CP administered group, expression of antiapoptotic protein Bcl-2 was lower than the controls (p=0.017).
In CP and TQ given group, there was an increased expression of Bcl-2 in myocardial fibers than the CP group (p=0.026) ( Figure 2C ).
Only TQ given group exhibited an increment in Bcl-2 expression ( Figure 2D ), when compared with the CP group (p=0.017). The related scores were given in Table 1 . 
Discussion
Gradually Cardiotoxicity sustains a significant issue because of a high correlation between the stage of heart injury and the dosage of CP utilized 22 . CP is one of the most related chemotherapeutic agents with atrial fibrillation and it can improve the production of thromboxanes by platelets, activate platelet aggregation and induce thrombotic arachidonic acid pathway 23, 24 . Dolci et al. 20 have classified the chemotherapy induced cardiotoxicity in two patterns: (1) Acute or subacute cardiotoxicity and (2) CP-induced cardiotoxicity is related to excessive oxidative stress and apoptosis 25 . Ma et al. 6 have reported that depressed cardiomyocyte contraction and mitochondrial abnormalities, increased endoplasmic reticulum stress and associated apoptosis caused cardiac damage following CP treatment. Cardiomyocytes containing numerous mitochondria constitute an important site for CP accumulation and this condition eventually can lead to mitochondrial DNA damage 26 . In some previous studies, it has been reported that a considerable incrementing caspase-3 activity, marked nuclear DNA fragmentation and reduced cardiomyocyte numbers were observed in the cross-sectional evaluation of the heart tissues following CP administration, which in turn may suggest apoptotic cell death [27] [28] [29] . Also, degradation of the mitochondrial transmembrane potential by cisplatin may give rise to a disruption in mitochondrial functionality and thereby trigger apoptosis.
TQ can potentiate the effect of conventional chemotherapeutic drugs. Its utilization in combined therapies may be at lower dosage, reduce the dosage of the concomitant drug optimizing efficacy and toxicity and it might also overcome the drug resistance problem 30, 31 . In previous studies, it has been reported that TQ led to a decrease in mean arterial blood pressure and heart rate in hypertensive rats in a dose dependent manner isoproterenol, cyclophosphamide and doxorubicin [33] [34] [35] .
In the current study, protective effect of TQ in myocardial tissue was showed by light microscopic examination.
In CP administered group, there were prominent histopathological changes including congestion, edema, pycnotic nuclei and eosinophylic appearance in myocardial tissues. However, it has been shown that TQ exhibited counteraction against the mentioned changes associated with CP administration. In our study, normal myocardial morphology structure was observed in rats treated with TQ.
Bcl-2 is considered to be an important cellular component that not only guards against apoptotic cell death, but also impinges on multiple cellular events. It was reported that the prevention of apoptosis is associated with increased abundance of Bcl-2 and decreased levels of Bax 36 . Various substrates like bax, bak and caspase trigger the apoptotic process; however bcl-2, bcl-xL or mcl-1 family proteins generally act as antiapoptotic mediators, which may cause delay or inhibition in apoptotic enzyme release.
Moreover, overexpression of antiapoptotic proteins provide a survival benefit in cells treated with chemotherapeutic agents 37 .
Wetzel and Berberich 37 have reported that cisplatin-induced apoptosis was believed to be the result of DNA damage in remaining survivor cells. CP binds to the nuclear and mitochondrial DNA of the neurons, which may trigger the activation of RhoA GTPase enzyme and induction of the inflammatory pathways 38, 39 . Nuclear DNA damage leads to p53 activation and triggers apoptosis. Taken together, these results suggest that increase in bax activity may be correlated with CP-induced apoptosis.
In this study, we have observed that TQ treatment significantly increased the antiapoptotic Bcl-2 expression, which was mainly reduced by CP administration alone and we have also found that the amount of apoptotic cardiomyocytes were remarkably higher in the CP group. TQ treatment reduced the reactivity and the number of apoptotic cardiomyocytes. Given these results, it can be suggested that TQ has antiapoptotic and protective properties. To best of our knowledge, this would be the first study to evaluate the antiapoptotic and protective effects of TQ against myocardial damage induced by CP in rats. We have observed that single dose of CP (15 mg/kg) led to severe heart injury in rats and that TQ established a prominent protective effect against this insult. CP-based treatment is very effective in different cancer types involving pulmonary, ovarian, cranial, cervical and gastric tissues cancers and its clinical use is gradually increasing. In the current study, we observed CP can be cardiotoxic and it could also trigger apoptosis in myocytes especially at higher doses. Cardiotoxic aspect of CP should be kept in mind when CP treatment is planned for patients with oncological conditions. More comprehensive studies are required in which different and multiple doses of CP and TQ would be administered in various time lapses in order to get more insight into the underlying mechanisms by which TQ exerts its protective effect against CPinduced myocardial damage.
Conclusion
Thymoquinone attenuated cardiomyocyte necrosis and apoptosis induced by cisplatin treatment.
